Evidence map›Paper›PMID 39965512›Full record

ArticleSeminars in arthritis and rheumatism2025

Impact of long COVID on self-reported disease activity, disability, and quality of life in individuals with inflammatory arthritis.

Zachary S Wallace, Miao Lin, Shruthi Srivatsan, Andrew King, Xiaosong Wang, Rathnam Venkat, Yumeko Kawano, Madison Negron, Buuthien Hang, Abigail Schiff and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Seminars in arthritis and rheumatism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Zachary S WallaceDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Miao LinDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Shruthi SrivatsanDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Andrew KingDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Xiaosong WangDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
Rathnam VenkatDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
Yumeko KawanoDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
Madison NegronDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Buuthien HangDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Abigail SchiffDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
Jennifer HanbergDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
Emily N KowalskiDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
Colebrook JohnsonDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Kathleen M M VanniDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
Zachary WilliamsDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Grace QianDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
Caleb BoldenDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Kevin T MuellerDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
Katarina J BadeDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
Alene A SaavedraDivision of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA.
Naomi J PatelDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Jeffrey A SparksHarvard Medical School, Boston, MA, USA; Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: jsparks@bwh.harvard.edu.

Funding

VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8M
Joint Biology Consortium Resource-based CenterP30AR070253 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic, Jeffrey Andrew Sparks · 2016 to 2026
$9.4M
Rheumatoid Arthritis-Related Autoantibodies, Articular Inflammation, and RA-Associated Interstitial Lung DiseaseR01AR077607 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SPARKS, JEFFREY ANDREW · 2021 to 2025
$3.7M
Rheumatoid Arthritis-associated Parenchymal Lung Disease: Clinical and Molecular PhenotypesR01HL155522 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Jeffrey Andrew Sparks, George R Washko · 2022 to 2026
$3.5M
Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic DiseasesR01AR080659 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Jeffrey Andrew Sparks · 2023 to 2026
$2.9M
NHLBI NIH HHS R01 HL155522NIAMS NIH HHS P30 AR070253NIAMS NIH HHS P30 AR072577NIAMS NIH HHS R01 AR077607NIAMS NIH HHS R01 AR080659
6 · The paper itself

Abstract

backgroundPeople with inflammatory arthritis are at risk for poor COVID-19 outcomes. Little is known about the impact of long COVID on disease activity, disability, and quality of life in this population.

methodsWe included participants with rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, or axial spondyloarthritis from RheumCARD, a prospective cohort study of people with rheumatic disease with and without prior COVID-19. Long COVID was defined as any symptom of acute COVID-19 for ≥90 days. Surveys include the Routine Assessment of Patient Index Data 3 (RAPID-3), modified health assessment questionnaire (MHAQ), short form-12 (SF-12), fatigue symptom inventory, and short form McGill Pain Questionnaire. We assessed the association of long COVID status with these outcomes.

resultsWe analyzed n = 59 with long COVID, n = 165 without long COVID, and n = 59 without prior COVID-19. The most common long COVID symptoms were fatigue (37.3 %), altered smell/taste (27.1 % and 25.4 %), difficulty breathing (20.3 %), and headache (15.3 %). Those with vs. without long COVID had worse mHAQ (median 0.4 vs. 0.1, p < 0.001), RAPID-3 (4.0 vs. 2.3, p = 0.0005), and physical and mental health (SF-12: 37.7 vs. 47.2, p = 0.0003 and 45.3 vs. 53.0, p = 0.003, respectively). Fatigue and pain were worse in those with vs. without long COVID (p < 0.05 for comparisons). Similar trends were observed in those with long COVID vs. those without prior COVID-19.

conclusionLong COVID may result in worsened pain, fatigue, and quality of life in people with inflammatory arthritis. Patient-reported outcomes should be interpreted with caution in people with inflammatory arthritis because of the impact of long COVID.

Indexed as

Arthritis, JuvenileArthritis, PsoriaticArthritis, RheumatoidCOVID-19Quality of LifeAdultDisability EvaluationFatigueFemaleHumansMaleMiddle AgedPost-Acute COVID-19 SyndromeProspective StudiesSARS-CoV-2Self ReportCOVID-19long COVIDpatient-reported outcomessymptoms

Identifiers

PMID39965512
PMCPMC11885002

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.